Detection of soluble fibrin by enzyme immunoassay

Dinh, Duong Thi Thuy; Bolitho, J.; Bundesen, P.; Hillyard, C. J.; Marsh, Neville; Moore, Bryant M.; Bottenus, Ralph E.; Rylatt, Dennis B.

doi:10.1016/0268-9499(94)90634-3

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The panspecific tagging antibody DD-4D2/182 binds to an epitope in the D domain present on soluble fibrin as well as fibrinogen and its derivatives (33). The assay as configured shows no reaction with fibrinogen, fibrinogen degradation products or cross-linked fibrin derivatives and in 93 normal subjects, had a reference range of 0.69 ± 0.38 pg/ml (34). The assay has an intra-assay variation of 9.77 ± 1.95% and an inter-assay variation of 9.4 ± 4.5% (unpublished information).…”

Section: Laboratory Interventionmentioning

confidence: 99%

Evaluation of a Soluble Fibrin Assay in Patients with Suspected Pulmonary Embolism

et al. 1996

View full text Add to dashboard Cite

SummaryIn order to determine the clinical utility of an enzyme immunoassay (EIA) for soluble fibrin in patients with suspected pulmonary embolism (PE), 195 unselected patients with suspected PE underwent blood sampling for measurement of plasma levels of soluble fibrin, and objective testing for PE. A soluble fibrin result of ≤ 0.75 Μg/ml showed a sensitivity of 100% for PE and a specificity of 12.8%, whereas a soluble fibrin result of ≤ 1.35 Μg/ml showed a sensitivity of 90.3% and a specificity of 49.4% for PE. The soluble fibrin assay has potential clinical utility in excluding PE.

show abstract

Section: Laboratory Interventionmentioning

confidence: 99%

Evaluation of a Soluble Fibrin Assay in Patients with Suspected Pulmonary Embolism

et al. 1996

View full text Add to dashboard Cite

show abstract

Markers of Thrombosis and Fibrinolysis

Lee¹,

Abendschein²,

Eisenberg³

Developments in Cardiovascular Medicine

View full text Add to dashboard Cite

The Relationship of Soluble Fibrin and Cross-linked Fibrin Degradation Products to the Clinical Course of Myocardial Infarction

Lee

Ewald

McKenzie

et al. 1997

ATVB

View full text Add to dashboard Cite

Recently, increases in the plasma concentration of soluble fibrin (SF) have been suggested to be sensitive and specific for myocardial infarction (MI). However, the relationship between elevations in the SF concentration and the onset of symptoms and clinical course of MI is unknown. In addition, there are no data regarding the relationship between SF concentrations and concentrations of other markers of procoagulant (fibrinopeptide A [FPA]) and fibrinolytic (cross-linked fibrin degradation products [XL-FDPs]) activity in patients with MI. In this study, concentrations of SF were measured with a novel antigen-based assay for 93 MI patients and 29 control subjects, and the relationship between SF concentrations and those of XL-FDPs and FPA was determined. Increases in SF, FPA, and XL-FDP concentrations were documented in 55.9%, 45.2%, and 73.9%, respectively, of patients with MI, but there was no relationship between the concentrations of these markers. Increases in the concentration of SF or XL-FDPs did not show a relationship to increases in the concentration of FPA. Concentrations of XL-FDPs but not of SF were elevated to a greater extent in patients with MI complications (defined as death, ventricular arrhythmia, severe congestive heart failure, or mural thrombus). Increases in SF and XL-FDPs were not sensitive enough for the diagnosis of MI, but increased concentrations of XL-FDPs appear to predict those patients who are at higher risk for MI-related complications.

show abstract

Detection of soluble fibrin by enzyme immunoassay

Cited by 3 publications

References 0 publications

Evaluation of a Soluble Fibrin Assay in Patients with Suspected Pulmonary Embolism

Evaluation of a Soluble Fibrin Assay in Patients with Suspected Pulmonary Embolism

Markers of Thrombosis and Fibrinolysis

The Relationship of Soluble Fibrin and Cross-linked Fibrin Degradation Products to the Clinical Course of Myocardial Infarction

Contact Info

Product

Resources

About